Reported Earlier, Quest Diagnostics Prices $1.85B Senior Notes Due 2027, 2029, And 2034
Portfolio Pulse from Benzinga Newsdesk
Quest Diagnostics (NYSE:DGX) has announced the pricing of a public offering of $1.85 billion in senior notes due 2027, 2029, and 2034. The notes include $400 million of 4.600% senior notes due 2027, $600 million of 4.625% senior notes due 2029, and $850 million of 5.000% senior notes due 2034.
August 16, 2024 | 7:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quest Diagnostics has priced $1.85 billion in senior notes, which could provide the company with significant capital for future investments or debt refinancing.
The issuance of senior notes will provide Quest Diagnostics with substantial capital, which can be used for various strategic purposes such as investments, acquisitions, or debt refinancing. This is likely to be viewed positively by investors as it strengthens the company's financial position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100